Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2
Elecsys IGRA SARS-CoV-2 testsupports the better understanding of immuneresponse to SARS-CoV-2 infection or vaccinationThe test detects T-cell response, which may play an important role in determining if immune protection has been achievedThenew diagnostic testmayprovide clinical care guidance, particularly forimmunocompromised and high-risk patient groupsBasel, 15 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® IGRA SARS-CoV-2 test in countries that accept the CE Mark1. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection...
Source: Roche Investor Update - August 15, 2022 Category: Pharmaceuticals Source Type: news
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of ageThe FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected personBasel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years o...
Source: Roche Investor Update - August 12, 2022 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s Pharma Day 2022
The Roche Investor Relations team would like to invite you to theRoche Pharma Day that will take place in London on Monday, 12th September 2022, starting at 10:30 BST and will finish at 14:30 BST with a reception.The Roche Pharma Day will address the following topics: Pharma strategy, portfolio planning, productivity& new technologiesMarket opportunities, on-going launches, pricing& accessLate stage pipeline update in oncology, neuroscience, immunology, infectious diseases& ophthalmology Speakers will include Bill Anderson, Teresa Graham, Levi Garraway, Paulo Fontoura and Christopher Brittain. You will ...
Source: Roche Investor Update - August 3, 2022 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
Vabysmo (faricimab) simultaneously targets and inhibits two disease pathways that driveneovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)The CHMP recommendation is based on results across four phase III studies: TENAYA and LUCERNE innAMD at year one, and YOSEMITE and RHINE in DME up to two yearsThe totality of the data across all studies innAMD and DME available to date showed that over 60% of people treated withVabysmo were able to extend treatment to every four months, while improving and maintaining visionIf approved,Vabysmo would offer the first new mechanism of action in ...
Source: Roche Investor Update - July 22, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023
Christoph Franz has decided not to seek re-election to the Board of Directors at the Annual General Meeting (AGM) in March 2023The Board of Directors intends to proposeSeverin Schwan as new Chairman at the Annual General MeetingThe Board of Directors has appointed ThomasSchinecker as the new Roche CEO effective 15 March 2023Basel, 21 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Christoph Franz has decided not to seek re-election to the Board of Directors at the AGM in March 2023. The Board of Directors intends to propose Severin Schwan as new Chairman at the AGM and has appointed Thomas Schinecker as...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual Analyst and Investor Event on Diagnostics Division at AACC 2022
We are pleased to invite you to a virtual analyst and investor event onTuesday,26 July 2022, to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 24-28, 2022).Please note that since the overwhelming majority of registrations was for a virtual participation, it has been decided to switch the event to a virtual format only (no on site event).6:00 - 7:15 pm CDT / 7:00 - 8:15 pm EDT / 4:00 - 5:15 pm PDTAACC brings together the global leaders in clinical chemistry, molecular diagnostics and ...
Source: Roche Investor Update - July 19, 2022 Category: Pharmaceuticals Source Type: news
Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer ’s disease
The Elecsys Amyloid Plasma Panel is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer ' s disease and other causes of cognitive decline.The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.This minimally invasive blood-based biomarker test can help to streamline a patient ' s journey, improving access to diagnosis and helping them better plan for the future.Basel, 19 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...
Source: Roche Investor Update - July 19, 2022 Category: Pharmaceuticals Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Investor Update - July 18, 2022 Category: Pharmaceuticals Source Type: news
New two-year data confirm Roche ’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration
In the TENAYA and LUCERNE studies, more than 60% ofVabysmo patientscould be treated every four months at two years. This represents an increase from 45% at year onePatients treated withVabysmo received a median number of 10 injections over the two years versus 15 injections for those treated withaflibercept, potentially decreasing the number of injectionsNo new safety signals were identified andVabysmo continued to be well tolerated, with afavourable benefit-risk profileBasel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term...
Source: Roche Investor Update - July 14, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s Half Year Results 2022 Webinar
Roche will publish its Half Year Results of 2022 prior to the opening of the Swiss Stock Exchange onThursday, 21 July 2022.07:00 CEST / 06:00 BST / 01:00 AM EDT / 10:00 PM PDT (evening before)Release will be e-mailed and posted on the Roche IR website>click herePresentation slides will be posted on the Roche IR website>click here14:00 – 15:30 CEST / 13:00 – 14:30 BST08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDTThe webinar will start with presentations by senior management,followed by a Q&A session.Presenters:Severin Schwan, CEO Roche GroupBill Anderson, CEO Roche PharmaceuticalsThomas Schinecker, CEO Roc...
Source: Roche Investor Update - July 14, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual Analyst and Investor Event on Diagnostics Division at AACC 2022
We are pleased to invite you to a virtual analyst and investor event onTuesday,26 July 2022,to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 24-28, 2022).Please note that since the overwhelming majority of registrations was for a virtual participation, it has been decided to switch the event to a virtual formatonly(no on site event).6:00 - 7:15 pm CDT / 7:00 - 8:15 pm EDT / 4:00 - 5:15 pm PDTAACC brings together the global leaders in clinical chemistry, molecular diagnostics and la...
Source: Roche Investor Update - July 11, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual Analyst and Investor Event on Diagnostics Division at AACC 2022
We are pleased to invite you to a virtual analyst and investor event onTuesday, 26 July 2022, to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 24-28, 2022).Please note that since the overwhelming majority of registrations was for a virtual participation, it has been decided to switch the event to a virtual formatonly(no on site event).6:00 - 7:15 pm CDT / 7:00 - 8:15 pm EDT / 4:00 - 5:15 pm PDTAACC brings together the global leaders in clinical chemistry, molecular diagnostics an...
Source: Roche Investor Update - July 11, 2022 Category: Pharmaceuticals Source Type: news
New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A
Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mildhaemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up [1]New data also reinforceHemlibra ’sfavourable safety profile, with no new safety signals observed [1]There is limited information and treatment guidance on moderate and mildhaemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes [2]Hemlibra is approved to treat people of all ages withhaemophilia A with factor VIII inhibitors in more than 110 countries and for people of all ages without factor VIII in...
Source: Roche Investor Update - July 11, 2022 Category: Pharmaceuticals Source Type: news
